Deciphering interleukin 37's therapeutic potential: insights into alleviating inflammation in autosomal dominant polycystic kidney disease

We were intrigued by the article "Modulating Inflammation with Interleukin 37 Treatment Ameliorates Murine Autosomal Dominant Polycystic Kidney Disease," by Zylberberg et al.1 The study focused on the therapeutic potential of interleukin 37 (IL37) in autosomal dominant polycystic kidney disease (ADPKD).1 IL37, an anti-inflammatory cytokine, demonstrated promise in reducing collecting duct cyst burden by modulating the interferon signaling pathway in kidney resident macrophages.1 Notably, this modulation occurred without a concurrent increase in macrophage numbers, highlighting the nuanced and context-dependent impact of IL37b on the inflammatory milieu.